Judge Advanced Claims Against ExThera Medical
A federal judge allowed new claims in a lawsuit alleging the company falsely marketed its cancer treatment.
Updated on Oct. 9, 2026 in Cancer
A federal judge indicated she would advance negligence and wrongful death claims against ExThera Medical Corporation. The company is currently being sued for allegedly marketing its ONCObind treatment as a cure for metastatic cancer.
Why it matters
The ruling strengthens a lawsuit against a company accused of selling ineffective, high-cost medical treatments to vulnerable patients. It marks a significant shift in a case involving allegations that the company's actions led to the deaths of multiple patients.
Plaintiffs allege that ExThera Medical Corporation charged $45,000 per round for ONCObind treatments administered in Antigua. The case remains under investigation regarding whether these treatments caused the deaths of at least three patients.
The players
ExThera Medical Corporation
This is a medical company based in the Bay Area that faces allegations of falsely marketing a cancer treatment.
The details
The court reviewed a first amended complaint supported by testimony from doctors asserting that ExThera’s actions directly contributed to patient deaths. Plaintiffs also submitted evidence of promotional videos and website claims allegedly created by a former board member to support their allegations of fraud and product liability.
Timeline
Plaintiffs filed the lawsuit against ExThera in March 2025.
A judge dismissed several initial claims in May 2026.
The judge indicated her intent to advance additional claims on October 9, 2026.
The Big Picture
This case follows the pattern set by the 2018 Cyclospora outbreak linked to McDonald's salads, where specialized litigation is required to hold entities accountable for health-related harms. The court's decision reflects a broader trend of judicial scrutiny regarding medical marketing and consumer safety.
This litigation highlights the risks associated with seeking medical treatments outside of traditional regulated care settings. Patients and their families are reminded to verify clinical trial credentials and medical efficacy data before pursuing expensive out-of-pocket health procedures.
The takeaway
Patients suffering from metastatic cancer should remain cautious of treatments that promise curative results not backed by peer-reviewed evidence. Always consult with primary oncologists before traveling abroad for unregulated procedures or alternative therapies.
Further reading
For more information on legal developments in medical and oncology cases, visit Cancer.
Source note: This article includes information reported by Court House News Service.
